MARKET

IONS

IONS

Ionis Pharmaceuticals
NASDAQ
42.93
-0.98
-2.23%
After Hours: 43.88 +0.95 +2.21% 19:30 10/23 EDT
OPEN
43.80
PREV CLOSE
43.91
HIGH
43.80
LOW
42.58
VOLUME
3.02M
TURNOVER
--
52 WEEK HIGH
86.74
52 WEEK LOW
42.08
MARKET CAP
7.13B
P/E (TTM)
-12.3650
1D
5D
1M
3M
1Y
5Y
1D
Roche Reports Positive Phase III Data For Investigational IgAN Therapy Sefaxersen
NASDAQ · 7h ago
Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More
Seeking Alpha · 15h ago
Ionis Advances IgA Nephropathy Program With Positive Phase 3
TipRanks · 18h ago
Ionis Pharmaceuticals, Inc. Partner Roche Announces Positive Phase 3 IMAgINATION Data for Sefaxersen in IgA Nephropathy
NASDAQ · 18h ago
Roche says Sefaxersen trial shows meaningful reduction in proteinuria
TipRanks · 18h ago
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)
Barchart · 23h ago
This CME Group Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday
Benzinga · 1d ago
Midday Fly By: Meta, Tesla slipping after quarterly reports
TipRanks · 1d ago
More
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Webull offers Ionis Pharmaceuticals Inc stock information, including NASDAQ: IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.